PharmaShots | Incisive News in 3 Shots

Subscribe Now

Genentech

Genentech Reports the US FDA Acceptance of BLA for Crovalimab to Treat Paroxysmal Nocturnal Hemoglobinuria

Genentech Reports the US FDA Acceptance of BLA for Crovalimab to Treat Paroxysmal Nocturnal Hemoglobinuria

September 6, 2023

Genentech Reports Second Interim Analysis Results from the P-III Study (SKYSCRAPER-01) of Tiragolumab + Tecentriq for PD-L1-High Metastatic Non-Small Cell Lung Cancer

Genentech Reports Second Interim Analysis Results from the P-III Study (SKYSCRAPER-01) of Tiragolumab + Tecentriq for PD-L1-High M...

August 23, 2023

$Genentech’s Columvi (glofitamab-gxbm) Receives the US FDA’s Approval for Relapsed or Refractory Diffuse Large B-cell Lymphoma$

Genentech’s Columvi (glofitamab-gxbm) Receives the US FDA’s Approval for Relapsed or Refractory Diffuse Large B-cell Lymphoma

June 16, 2023

Insights+: The US FDA New Drug Approvals in April 2023

Insights+: The US FDA New Drug Approvals in April 2023

May 17, 2023

Genentech Reports the US FDA Acceptance of sBLA for Vabysmo to Treat Retinal Vein Occlusion

Genentech Reports the US FDA Acceptance of sBLA for Vabysmo to Treat Retinal Vein Occlusion

May 9, 2023

Genentech’s Polivy (polatuzumab vedotin) Receives the US FDA’s Approval for Diffuse Large B-cell Lymphoma

Genentech’s Polivy (polatuzumab vedotin) Receives the US FDA’s Approval for Diffuse Large B-cell Lymphoma

April 20, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us